Overview
Join us as members of the IASLC Education Committee moderate the program and lead discussions, including a Q&A session, following panel presentations by Jacob Sands, MD, Xiuning Le, MD, PhD, and Patrick Forde, MBBCH. The event will cover key topics and provide a summary of the insightful presentations from the recent IASLC World Conference on Lung Cancer.
At the end of the webinar, learners will be able to:
- Identify key findings from the newest clinical trials on early-stage and locally advanced NSCLC presented at WCLC 2024.
- Describe the latest clinical trial results related to driver-negative NSCLC as presented at WCLC 2024.
- Explain the clinical advancements in driver-positive NSCLC based on the newest trials presented at WCLC 2024.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
At the end of the webinar, learners will be able to:
- Identify key findings from the newest clinical trials on early-stage and locally advanced NSCLC presented at WCLC 2024.
- Describe the latest clinical trial results related to driver-negative NSCLC as presented at WCLC 2024.
- Explain the clinical advancements in driver-positive NSCLC based on the newest trials presented at WCLC 2024.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.